Page last updated: 2024-12-07

4'-iodo-4'-deoxydoxorubicinol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

4'-iodo-4'-deoxydoxorubicinol: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID9874402
MeSH IDM0171899

Synonyms (7)

Synonym
111865-30-6
4'-deoxy-4'-iododoxorubicinol
4'-iddr
5,12-naphthacenedione, 10-((4-aminotetrahydro-5-iodo-6-methyl-2h-pyran-2-yl)oxy)-8-(1,2-dihydroxyethyl)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-
4'-iodo-4'-deoxydoxorubicinol
(7s,9s)-7-[(2r,4s,5s,6s)-4-amino-5-iodo-6-methyloxan-2-yl]oxy-9-(1,2-dihydroxyethyl)-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione
4/'-iodo-4/'-deoxydoxorubicinol

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Treatments induced a significant widening of the S alpha T segment, but I-DXRol was significantly less toxic than I-DXR or DXR."( Cardiac toxicity and antitumor activity of 4'-deoxy-4'-iodo-doxorubicinol.
Bernardini, N; Bevilacqua, G; Danesi, R; Del Tacca, M; La Rocca, RV; Marchetti, A, 1990
)
0.28

Pharmacokinetics

ExcerptReferenceRelevance
"4); the metabolite was cleared from the plasma with an elimination half-life of 15."( Pharmacokinetics and metabolism of 4'-iodo-4'-deoxy-doxorubicin in humans.
Armand, JP; Huet, S; Hurteloup, P; Klink-Alakl, M; Recondo, G; Robert, J, 1992
)
0.28
" The pharmacokinetic parameters also implied metabolic differences between species."( Pharmacokinetics of iododoxorubicin in the rat, dog, and monkey.
Basileo, G; Edwards, DM; Efthymiopoulos, C; Fraier, D; Marrari, P; Pianezzola, E; Strolin-Benedetti, M,
)
0.13
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (4)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (25.00)18.7374
1990's3 (75.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (20.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other4 (80.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]